Chemotherapy plus RA223 in the treatment of oat cell lung cancer

A. Lipton, H. A. Harvey, B. Walker, R. Dixon, D. Valdivia, S. Barnes, R. Gordon, D. White-Hershey, M. J. Bartholomew, N. Warzawski, C. E. Antle

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.

Original languageEnglish (US)
Pages (from-to)259-263
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number3
DOIs
StatePublished - Jan 1 1989

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lipton, A., Harvey, H. A., Walker, B., Dixon, R., Valdivia, D., Barnes, S., Gordon, R., White-Hershey, D., Bartholomew, M. J., Warzawski, N., & Antle, C. E. (1989). Chemotherapy plus RA223 in the treatment of oat cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 12(3), 259-263. https://doi.org/10.1097/00000421-198906000-00016